Journal of Biological Chemistry
Volume 270, Issue 46, 17 November 1995, Pages 27948-27953
Journal home page for Journal of Biological Chemistry

Nucleic Acids, Protein Synthesis, and Molecular Genetics
A Novel Promoter for Vascular Endothelial Growth Factor Receptor (flt-1) That Confers Endothelial-specific Gene Expression (*)

https://doi.org/10.1074/jbc.270.46.27948Get rights and content
Under a Creative Commons license
open access

The human transmembrane fms-like receptor tyrosine kinase Flt-1 is one of the receptors for vascular endothelial growth factor, a growth factor which induces endothelial proliferation and vascular permeability. Flt-1 is expressed specifically in endothelium and is likely to play a role in tumor angiogenesis and embryonic vascularization. To elucidate the molecular basis for the endothelial specific expression of Flt-1, the promoter region has been isolated and functionally characterized. The promoter region contains a TATA box, a GC-rich region, and putative transcription factor binding elements such as cAMP response element binding protein/activating transcription factor (CREB/ATF) and ets. Adenovirus-mediated transient expression of the flt-1 promoter/luciferase fusion gene in endothelial cells and other cell types demonstrated that a 1-kilobase fragment of the 5′-flanking region of flt-1 is involved in the endothelial-specific expression. A CREB/ATF element was found to be essential for basal transcription of the flt-1 expression. In addition, we also showed that the first intron negatively regulates flt-1 promoter activity. The flt-1 promoter will be useful in functional studies on the regulation of endothelial-specific gene expression and also as a tool in targeting the expression of exogenously introduced genes to the endothelium.

Cited by (0)

*

This work was supported in part by a fund provided by Daiichi Pharmaceuticals and National Institutes of Health Grant HL43821 (to L. T. W.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EMBL Data Bank with accession number(s) D64016.

§

Present address: Daiichi Pharmaceutical Co., Ltd. 1-16-13, Kita-Kasai, Edogawa-ku, Tokyo, 134, Japan.

Present address: Dept. of Medicine, University of Pittsburgh, Pittsburgh Cancer Institute, 211 Lothrop St., Pittsburgh, PA 15261-2592.